Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.
about
Pharmacologic interventions for the prevention and treatment of retinopathy of prematurityCOMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY.Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study.Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity.Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.Treatment for stage 4A retinopathy of prematurity: laser and/or ranibizumab.Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.Retinopathy of Prematurity among Very-Low-Birth-Weight Infants in Korea: Incidence, Treatment, and Risk Factors.Intravitreal anti-VEGF treatment for retinopathy of prematurity in infants with active adenoviral keratoconjunctivitis.Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of PrematurityResults of intravitreal ranibizumab treatment for retinopathy of prematurity in infants.Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
P2860
Q26772889-41C09A6F-5EA5-4514-99A7-2FF4B051A898Q33552891-59B8E85C-FF28-4627-B1FC-B3ECA5E85CAEQ33592995-4A9EC706-1FD9-4421-B01B-F859799219A8Q35950878-5A2482EC-BC56-4032-AAC1-EF1D7D035B3CQ36078573-E0E265D0-BC94-4DE8-AD8F-509A55298547Q36096360-56EBEF3C-40BA-4D1F-A938-6A086A49F773Q36262336-0EF611C5-F672-43F6-9C9E-43B0C2315277Q36269460-FE629F7B-AE63-4B37-82E6-10802A2103ECQ36341771-4567015C-87D2-4800-8071-FBE51BA15B64Q37487675-181195A3-ECF3-4A63-8FC1-9F19D941A69AQ50853137-015003ED-BE0D-4BA3-A955-3D826E1435D6Q55470224-59839341-8740-4FDE-BCA1-02803EF707F0
P2860
Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Intravitreal ranibizumab monot ...... II, stage 3 with plus disease.
@ast
Intravitreal ranibizumab monot ...... II, stage 3 with plus disease.
@en
type
label
Intravitreal ranibizumab monot ...... II, stage 3 with plus disease.
@ast
Intravitreal ranibizumab monot ...... II, stage 3 with plus disease.
@en
prefLabel
Intravitreal ranibizumab monot ...... II, stage 3 with plus disease.
@ast
Intravitreal ranibizumab monot ...... II, stage 3 with plus disease.
@en
P2093
P2860
P1433
P1476
Intravitreal ranibizumab monot ...... II, stage 3 with plus disease
@en
P2093
Carsten Framme
Marcel N Menke
Markus R Berger
Mathias Nelle
Veit Sturm
P2860
P2888
P356
10.1186/S12886-015-0001-7
P577
2015-03-08T00:00:00Z
P5875
P6179
1045704060